At what enterprise value was THERADIAL acquired in 2023?

You can find the full valuation details of THERADIAL on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of THERADIAL when it was acquired by ARDIAN?

The exact EV/EBITDA multiple for THERADIAL is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was THERADIAL acquired by ARDIAN?

THERADIAL was acquired by ARDIAN in 2023.

What was the revenue of THERADIAL at the time of the deal?

The revenue of THERADIAL at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the THERADIAL acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the THERADIAL deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.decideurs-magazine.com/finance/54570-theradial-accueille-ardian-a-son-capital-2.html

← DATABASE

Home Database Healthcare & PharmaTHERADIAL

02/2023

THERADIAL acquired by ARDIAN

FRANCE Life Sciences / Medical Devices REV 50M - 100M EUR

Context

Ardian has acquired a stake in Théradial, a specialized player in the French dialysis sector, with a consolidated presence in medical product distribution, pharmaceuticals, and healthcare software. This transaction is part of a strategic partnership with UI Investissement, which had previously invested in the company in 2017. Founded in 1998, Théradial employs around 90 staff in France and Italy, generating approximately 50 million euros in revenue, primarily from public healthcare establishments, private clinics, and home care service providers. Ardian's strategy aims to structure Théradial's growth, notably through organic development of its medical product activities and targeted acquisitions. This operation will enable Théradial to strengthen its market positioning and accelerate its development, particularly in nutrition and digital division, with the objective of entering new markets and diversifying its activities. The Ardian Growth team, led by Alexis Saada and Frédéric Quéru, will work closely with Théradial's management to implement this growth strategy, focusing on increasing revenue and improving the company's profitability. This operation is also expected to allow Théradial to consolidate its relationships with clients and suppliers, and reinforce its position in the French and Italian dialysis markets, with a view to expanding its customer base and enhancing its operational efficiency.

In the past, the company underwent an LBO led by Ui Investissement / Bpifrance in 2017, and continued an active consolidation strategy by notably acquiring Groupe ThéMa (2019).

THERADIAL, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Theradial, a medical device distribution firm focused on dialysis equipment, has undergone substantial development over the years. Initially concentrated on supplying medical devices to public health institutions, private clinics, and home care providers, the company gradually expanded its scope of activities. It now offers medications and software tailored to dialysis centers, enabling it to address the specific needs of its clients. By diversifying its product portfolio, Theradial has enhanced its capability to cater to a broader range of customers. The company has also collaborated with pharmaceutical laboratory Indigo Therapeutics to develop nutritional supplements for patients undergoing dialysis, thereby broadening its offerings to include complementary healthcare products. This strategic move has allowed Theradial to deepen its understanding of the dialysis treatment process and provide more comprehensive solutions to its customers, ultimately refining its operational capabilities and reinforcing its position in the medical device distribution sector.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Other operations with THERADIAL

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
03/2019	THERADIAL	GROUPE THÉMA	FRANCE	Software	This growth transaction marks a significant evolution for Théradial, transitioning from a specialized medical device distributor to a provider of an integrated ecosystem encompassing care equipment and clinical operation digital solutions. The acquisition of Groupe Théma is financed through a hybrid structure combining cash contribution and share exchange for the selling founders, as well as an extension of senior debt lines granted by the acquirer's historical banking pool. The underlying financial analysis is based on creating a significant competitive advantage by integrating medical consumables logistics flows into dialysis center management software interfaces, which will increase switching costs for hospital clients
10/2017	UI INVESTISSEMENT / BPIFRANCE	THERADIAL	FRANCE	Life Sciences	Théradial has completed a shareholder restructuring agreement, welcoming UI Gestion and Bpifrance as new majority shareholders. This transaction is part of a management buy-out, enabling Frédéric Le Pottier, the former Commercial Director, to take the helm as Chairman of the Executive Board. Meanwhile, Bruno Duval, the company's founder, will retain a key role as a shareholder and become Chairman of the Supervisory Board. The goal of this transaction is to support Théradial's growth strategy, which aims to leverage its pharmaceutical establishment status, obtained two years ago, to expand its product portfolio

REFERENCES

Revenue range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of THERADIAL by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: theradial

Acquirer: ardian